Over the past decade, postbiotics have transformed from a relatively unknown scientific concept into one of the most dynamic frontiers of health and nutrition. The momentum is unmistakable: scientific publications mentioning postbiotics have surged from less than 30 before 2010 to 887 in 2024, with projections to exceed 1000 by 2025. This rapid growth reflects not only academic curiosity but also rising confidence across the food and beverage industry that postbiotics are here to stay.

The real inflection point came in 2021, when the International Scientific Association for Probiotics and Prebiotics (ISAPP) published the first consensus definition: “a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host.”[1] Before this, the lack of clarity hampered industrial application, companies hesitated to invest without a clear regulatory or scientific framework. With a definition in place, research and product development accelerated rapidly, leading to increased clinical validation and an expanding pipeline of postbiotic-enriched products across multiple categories. For companies navigating this fast-moving field, the combination of solid science and regulatory expertise has become crucial to de-risk innovation and accelerate time to market.
​​​​​​​

Several factors may explain why postbiotics are gaining traction among researchers, regulators, and industry leaders alike. Firstly, human intervention trials, particularly with heat-treated strains and/or their components, have reported benefits not only in gut health but also in areas far beyond, such as endurance, reduced fatigue, and stress[2]. In fact, clinical trials have often shown that postbiotics are similarly effective as their live counterparts, probiotics, in supporting gut, immune, metabolic, and even mental health[1,3]. This broadens the narrative from “gut health only” to a more holistic story spanning immune, metabolic, muscle and even mental health. Some postbiotics even link into the growing interest in GLP-1 agonists, appetite regulation and metabolic outcomes[4], further increasing relevance. Secondly, unlike probiotics, postbiotics cannot replicate in the body. This eliminates risks such as sepsis, fungaemia, or the transfer of antibiotic resistance [5].

Regulatory experience also suggests that achieving safety approval for inanimate bacteria may be more straightforward than for live organisms. Indeed, the European Food Safety Authority (EFSA) has already issued positive safety assessments for inactivated Bacteroides xylanisolvens and Akkermansia muciniphila preparations, both now authorized for use in the EU. Thirdly, heat stability and pH tolerance mean postbiotics withstand processing conditions that would otherwise destroy live microbes. This opens opportunities in baked goods, bars, and shelf-stable beverages, while reducing cold chain costs. Their ease of standardization, storage, and transport further enhances their commercial appeal.

Despite this promise, postbiotic innovation is not without hurdles. Transitioning from the well-established “CFU” count used for probiotics to meaningful units for inactivated biomass (such as mg of standardized biomass or total cell equivalents) requires validated enumeration methods and strict batch consistency. The solution lies in setting clear inactivation parameters, release specifications tied to biomarkers, and claim language aligned with clinical evidence. Formulators must also address sensory challenges: even heat-killed cells can impact mouthfeel or beverage clarity. Advances in strain selection, particle size optimization, microencapsulation, and light filtration are already providing solutions, with several beverage-ready postbiotics now commercially available. Finally, companies should resist the temptation to extrapolate probiotic data to postbiotic formats. Instead, successful innovation will be anchored in human evidence specifically generated with postbiotics. From a regulatory standpoint, this distinction is crucial: in the EU, use of the term “postbiotic” in foods or supplements will likely require EFSA-approved health claims and systematic novel food applications. Strategic guidance on claim substantiation and dossier preparation is therefore becoming a key enabler for companies aiming to enter this space.

Postbiotics are already making their mark across diverse product categories globally. Fermented infant formulas containing the postbiotic human milk oligosaccharide 3-GL, children’s drinks with heat-killed Lacticaseibacillus paracasei, and nutritional supplements with Akkermansia muciniphila are just a few examples. Multinationals such as Nestlé and Danone, alongside small and medium-sized enterprises and agile start-ups, are actively commercializing postbiotic-containing formulas, yoghurts, sports beverages, ready-to-drink formats. Even nutritional drinks for the health ageing population are nowadays present on the market. These examples illustrate how scientific findings can be translated into real-world products when supported by the right evidence base and innovation strategy.

What is particularly striking is the move toward combination products. Some launches now include blends of postbiotics with or without other biotics or bioactives, reflecting both scientific insights and consumer demand for multi-benefit solutions. This is consistent with ongoing clinical trials exploring mixes for synergistic effects across gut, immune, brain, and muscle health.

Looking ahead, several promising frontiers are emerging for postbiotics. Early evidence points to benefits in brain health, particularly in areas such as mood, stress, and anxiety—highly relevant in today’s fast-paced lifestyle. Muscle health is another area attracting growing interest, with studies focusing on endurance, strength, and muscle mass outcomes not only for athletes but also for the healthy ageing population. In addition, combinatorial approaches are gaining momentum, where postbiotics are paired with other biotics or functional bioactives to achieve product differentiation, broader health coverage, and stronger market positioning.

These directions align seamlessly with consumer expectations for holistic wellness solutions that go beyond gut health alone addressing immune, metabolic, brain, muscle, or skin health. Postbiotics have evolved from a niche curiosity into a more robust, evidence-based platform for innovation. They are backed by rapidly expanding human evidence, with manufacturing advantages and suitable for diverse product formats, from infant formula to sports nutrition and active ageing solutions.

For food and beverage leaders, the opportunity is twofold: respond to the science-driven demand for safe, effective biotics and leverage the versatility of postbiotics to expand into new health territories and formats. As research accelerates and consumer awareness grows, the coming years will likely see postbiotics move from “emerging” to “essential” in the functional nutrition toolbox. For innovators aiming to capture this momentum, partnering with experienced nutrition science consultancies can help bridge the gap between cutting-edge research, regulatory compliance, and successful product launches.

Obviously, implementing lifestyle as medicine at a large scale involves some hurdles. To overcome them, we will require innovation, creativity and ecosystem-thinking, combined with biomedical and digital technology and novel solutions from agri- and food. Moreover, new governmental policies should support such changes in order to sustain them.

One of the biggest challenges is the achievement of a long-term lifestyle behaviour change in people with a chronic disease. Here, personalisation comes into play. Ideally, biological cause as well as socioeconomic and cultural background, personality, preferences and goals should be considered in the treatment. In type 2 diabetes, for example, it is known that different subtypes of the disease exist with a different biological cause, etiology and complications, requiring a tailored treatment strategy. Furthermore, it is pivotal to make the invisible visible, especially to show the impact of the lifestyle treatment and a person’s behaviour on the biological cause of the disease. In particular, continuous monitoring coupled with just-in-time adaptive interventions have shown to be very powerful in lifestyle behaviour change and in stimulating people to regain to healthy habits in case of a relapse. Blended solutions, in which digital health innovations are combined with face-to-face contact from healthcare professionals, lifestyle coaches, peers, peer coaches or buddies showed to be scalable and cost-effective for lifestyle medicine.

The ‘magic pill’ for chronic, lifestyle-related diseases is personalised lifestyle medicine. For this, we need all of you! To achieve a healthy society in which we live long and in good health, we need to collaborate and combine forces to create fun, tasty, convenient and easy-to- adopt agri and food and high-tech solutions. If we work together, a very large market will welcome us and more importantly we can help to reduce the chronic disease burden and to maintain a high quality health care system.